Charlesbank-backed Tecomet and Nordic Capital-backed Orchid have agreed to merge, combining their medical technology capabilities. Tecomet, based in Wilmington, Massachusetts, specializes in precision components for medtech, aerospace, and defense. Orchid, located in Holt, Michigan, focuses on procedural solutions for major medtech markets across the US and Europe.

The merger aligns two portfolio companies from prominent private equity firms, reflecting a trend of consolidation in the medical technology supply chain. Both companies serve critical roles in delivering components and solutions to healthcare markets. Charlesbank has owned Tecomet since 2017, while Nordic Capital acquired Orchid in 2021.

Industry experts expect the combined entity to enhance service offerings and geographic reach within the medtech sector. The deal strengthens capabilities in high-growth medical device segments. Terms of the agreement were not disclosed. Regulatory approval and closing timelines remain pending.